When Facing Difficult-To-Treat Gram-Negatives

MERREM I.V. offers in vitro activity against certain difficult-to-treat gram-negative aerobic and anaerobic microorganisms.

In vitro activity does not necessarily correlate with clinical effectiveness.

* (n=number of isolates)
† Data from US MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) database provided by AstraZeneca, which tracks trends in microbial susceptibility to MERREM I.V. in US medical centers using carbapenem agents.

MERREM I.V. is Active Against Other Gram-Negatives ‡

100%
Haemophilus influenzae 7§
(n=199)

100%
Proteus mirabilis 6//
(n=147)

100%
Escherichia coli 6//
(n=491)

95.0%
Klebsiella pneumoniae 8//
(n=366)

‡(n = number of isolates)
§Data from the SENTRY Program 2000, which collected isolates from 30 medical centers in North America (US, 25; Canada 5).
//Data from US MYSTIC database 2005 provided by AstraZeneca, which tracks trends in microbial susceptibility to MERREM I.V. in US medical centers using carbapenem agents.

MERREM I.V. Has Demonstrated In Vitro Activity Against These Gram-Negative Microorganisms, But The Clinical Significance Of These Data Is Unknown 7

Aerobic and Facultative Gram-Negative Microorganisms 1

Acinetobacter species
Aeromonas hydrophila
Campylobacter jejuni
Citrobacter diversus
Citrobacter freundii
Enterobacter cloacae
Haemophilus influenzae (ampicillin-resistant, non-β-lactamase-producing isolates)
Hafnia alvei
Klebsiella oxytoca
Moraxella catarrhalis (β-lactamase- and non-β-lactamase-producing isolates)
Morganella morganii
Pasteurella multocida
Proteus vulgaris
Salmonella species
Serratia marcescens
Shigella species
Yersinia enterocolitica

In vitro activity does not necessarily correlate with clinical effectiveness.

Next Page > Gram-Positives